Close Menu

NEW YORK – Carisma Therapeutics said on Monday that it has, for the second time, closed a Series B equity financing round, bringing its total proceeds raised in the round to $59 million, which it will use to advance its macrophage-based cell therapy pipeline.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.